Author: Kibbee, R.B.
Paper Title Page
THPOMS035 First Production of Astatine-211 at Crocker Nuclear Laboratory at UC Davis 3038
 
  • E. Prebys, D.A. Cebra, R.B. Kibbee, L.M. Korkeila, K.S. Stewart
    UCD, Davis, California, USA
  • M.R. Backfish
    UC Davis, Davis, USA
 
  Funding: This work partially supported by the US DOE under contract DE-SC0020407
There is a great deal of interest in the medical community in the use of the alpha-emitter At-211 as a therapeutic isotope. Among other things, its 7.2 hour half life is long enough to allow for recovery and labeling, but short enough to avoid long term activity in patients. Unfortunately, the only practical technique for its production is to bombard a Bi-209 target with a ~29 MeV alpha beam, so it is not accessible to commercial isotope production facilities, which all use fixed energy proton beams. The US Department of Energy is therefore supporting the development of a "University Isotope Network" (UIN) to satisfy this need. As part of this effort, we have developed an At-211 production facility using the variable-energy, multi-species cyclotron at Crocker Nuclear Lab the University of California, Davis. This effort relies on a beam probe which has been modified to serve as an internal Bi-209 target, to avoid problems with alpha particle extraction efficiency. This poster will data on the first production and recovery of At-211 using this system.
 
DOI • reference for this paper ※ https://doi.org/10.18429/JACoW-IPAC2022-THPOMS035  
About • Received ※ 09 June 2022 — Revised ※ 15 June 2022 — Accepted ※ 15 June 2022 — Issue date ※ 03 July 2022
Cite • reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)